The stock of Novo Nordisk ADR (NVO) has seen a -0.94% decrease in the past week, with a 6.50% gain in the past month, and a 23.27% flourish in the past quarter. The volatility ratio for the week is 1.40%, and the volatility levels for the past 30 days are at 1.93% for NVO. The simple moving average for the past 20 days is -2.09% for NVO’s stock, with a 27.06% simple moving average for the past 200 days.
Is It Worth Investing in Novo Nordisk ADR (NYSE: NVO) Right Now?
Novo Nordisk ADR (NYSE: NVO) has a higher price-to-earnings ratio of 47.22x compared to its average ratio. NVO has 36-month beta value of 0.41. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for NVO is 3.38B, and currently, short sellers hold a 0.12% ratio of that float. The average trading volume of NVO on April 02, 2024 was 5.18M shares.
NVO) stock’s latest price update
Novo Nordisk ADR (NYSE: NVO) has experienced a decline in its stock price by -0.66 compared to its previous closing price of 128.40. However, the company has seen a fall of -0.94% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-01 that Novo Nordisk (NVO) closed at $127.55 in the latest trading session, marking a -0.66% move from the prior day.
Analysts’ Opinion of NVO
Many brokerage firms have already submitted their reports for NVO stocks, with Morgan Stanley repeating the rating for NVO by listing it as a “Overweight.” The predicted price for NVO in the upcoming period, according to Morgan Stanley is $120 based on the research report published on January 23, 2024 of the current year 2024.
Cantor Fitzgerald gave a rating of “Overweight” to NVO, setting the target price at $120 in the report published on December 01st of the previous year.
NVO Trading at 4.67% from the 50-Day Moving Average
After a stumble in the market that brought NVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.76% of loss for the given period.
Volatility was left at 1.93%, however, over the last 30 days, the volatility rate increased by 1.40%, as shares surge +2.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.60% upper at present.
During the last 5 trading sessions, NVO fell by -0.94%, which changed the moving average for the period of 200-days by +61.83% in comparison to the 20-day moving average, which settled at $130.44. In addition, Novo Nordisk ADR saw 23.30% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for NVO
Current profitability levels for the company are sitting at:
- 0.44 for the present operating margin
- 0.85 for the gross margin
The net margin for Novo Nordisk ADR stands at 0.36. The total capital return value is set at 0.71. Equity return is now at value 87.44, with 29.90 for asset returns.
Based on Novo Nordisk ADR (NVO), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at 4.03. The debt to equity ratio resting at 0.25. The interest coverage ratio of the stock is 69.78.
Currently, EBITDA for the company is 112.94 billion with net debt to EBITDA at 0.11. When we switch over and look at the enterprise to sales, we see a ratio of 17.1. The receivables turnover for the company is 3.09for trailing twelve months and the total asset turnover is 0.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.82.
Conclusion
To put it simply, Novo Nordisk ADR (NVO) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
